CoChat

SARS-CoV-2 infection in Africa: a systematic review and meta-analysis of standardised seroprevalence studies, from January 2020 to December 2021

Open access
Lewis, Hannah C, Ware, Harriet, Whelan, Mairead, Subissi, Lorenzo, Li, Zihan, Ma, Xiaomeng, Nardone, Anthony, Valenciano, Marta, Cheng, Brianna, Noel, Kim, Cao, Christian, Yanes-Lane, Mercedes, Herring, Belinda L, Talisuna, Ambrose, Ngoy, Nsenga, Balde, Thierno, Clifton, David, Van Kerkhove, Maria D, Buckeridge, David, Bobrovitz, Niklas, Okeibunor, Joseph, Arora, Rahul K, Bergeri, Isabel · 2022 · BMJ Global Health

Published version of a preprint

Cited by 173

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Introduction: Estimating COVID-19 cumulative incidence in Africa remains problematic due to challenges in contact tracing, routine surveillance systems and laboratory testing capacities and strategies. We undertook a meta-analysis of population-based seroprevalence studies to estimate SARS-CoV-2 seroprevalence in Africa to inform evidence-based decision making on public health and social measures (PHSM) and vaccine strategy. Methods: We searched for seroprevalence studies conducted in Africa published 1 January 2020–30 December 2021 in Medline, Embase, Web of Science and Europe PMC (preprints), grey literature, media releases and early results from WHO Unity studies. All studies were screened, extracted, assessed for risk of bias and evaluated for alignment with the WHO Unity seroprevalence protocol. We conducted descriptive analyses of seroprevalence and meta-analysed seroprevalence differences by demographic groups, place and time. We estimated the extent of undetected infections by comparing seroprevalence and cumulative incidence of confirmed cases reported to WHO.PROSPERO: CRD42020183634. Results: We identified 56 full texts or early results, reporting 153 distinct seroprevalence studies in Africa. Of these, 97 (63%) were low/moderate risk of bias studies. SARS-CoV-2 seroprevalence rose from 3.0% (95% CI 1.0% to 9.2%) in April–June 2020 to 65.1% (95% CI 56.3% to 73.0%) in July–September 2021. The ratios of seroprevalence from infection to cumulative incidence of confirmed cases was large (overall: 100:1, ranging from 18:1 to 954:1) and steady over time. Seroprevalence was highly heterogeneous both within countries—urban versus rural (lower seroprevalence for rural geographic areas), children versus adults (children aged 0–9 years had the lowest seroprevalence)—and between countries and African subregions. Conclusion: We report high seroprevalence in Africa suggesting greater population exposure to SARS-CoV-2 and potential protection against COVID-19 severe disease than indicated by surveillance data. As seroprevalence was heterogeneous, targeted PHSM and vaccination strategies need to be tailored to local epidemiological situations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmjgh-2022-008793

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Research works printed but not linked: 27

  1. 10.1136/bmj-2021-068123 · DOI
  2. Cohen, 2021, SARS-CoV-2 incidence, transmission and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020-2021, medRxiv
  3. Chisale, 2022, Seroprevalence of anti-SARS-CoV-2 antibodies in Africa: a systematic review and meta-analysis, Rev Med Virol, 32, 10.1002/rmv.2271 · DOI
  4. Bergeri, 2022, Early epidemiological investigations: World Health Organization UNITY protocols provide a standardized and timely international investigation framework during the COVID-19 pandemic, Influenza Other Respir Viruses, 16, 7, 10.1111/irv.12915 · DOI
  5. Bergeri I , Whelan M , Ware H . Global SARS-CoV-2 seroprevalence: a systematic review and meta-analysis of standardized population-based studies from Jan 2020-May 2022. medRxiv 2022.doi:https://doi.org/10.1101/2021.12.14.21267791 · DOI · Paper page
  6. 10.1016/j.jclinepi.2020.06.039 · DOI · Paper page
  7. Bobrovitz N , Noel KC , Li Z . SeroTracker-RoB: an approach to automating reproducible risk of bias assessment of seroprevalence studies. medRxiv 2022.doi:https://doi.org/10.1101/2021.11.17.21266471 · DOI
  8. 10.1002/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E · DOI · Paper page
  9. Karamagi, 2021, Towards universal health coverage in the WHO African Region: assessing health system functionality, incorporating lessons from COVID-19, BMJ Glob Health, 6, 10.1136/bmjgh-2020-004618 · DOI
  10. 10.1128/JCM.00767-21 · DOI
  11. Gudina, 2021, Seroepidemiology and model-based prediction of SARS-CoV-2 in Ethiopia: longitudinal cohort study among front-line hospital workers and communities, Lancet Glob Health, 9, e1517, 10.1016/S2214-109X(21)00386-7 · DOI
  12. Barrie, 2021, SARS-CoV-2 antibody prevalence in Sierra Leone, March 2021: a cross-sectional, nationally representative, age-stratified serosurvey, medRxiv
  13. Bobrovitz N , Arora RK , Yan T . Lessons from a rapid systematic review of early SARS-CoV-2 serosurveys. medRxiv 2020:20097451. · DOI · Paper page
  14. Arora, 2021, SeroTracker: a global SARS-CoV-2 seroprevalence dashboard, Lancet Infect Dis, 21, e75, 10.1016/S1473-3099(20)30631-9 · DOI · Paper page
  15. Borrega, 2021, Cross-reactive antibodies to SARS-CoV-2 and MERS-CoV in pre-covid-19 blood samples from Sierra leoneans, Viruses, 13, 10.3390/v13112325 · DOI
  16. 10.1016/j.ijid.2020.10.104 · DOI · Paper page
  17. Steinhardt, 2021, Cross-reactivity of two SARS-CoV-2 serological assays in a setting where Malaria is endemic, J Clin Microbiol, 59, 10.1128/JCM.00514-21 · DOI
  18. 10.1016/j.nmni.2020.100817 · DOI
  19. 10.7554/eLife.70330 · DOI
  20. 10.1038/s41590-021-01089-8 · DOI · Paper page
  21. 10.1186/s41118-021-00130-w · DOI
  22. 10.1007/s12646-021-00607-w · DOI
  23. 10.2471/BLT.20.265942 · DOI
  24. 10.5588/pha.20.0069 · DOI
  25. 10.1016/j.vaccine.2021.05.063 · DOI · Paper page
  26. Gao, 2022, Ancestral SARS-CoV-2-specific T cells cross-recognize the omicron variant, Nat Med, 28, 472, 10.1038/s41591-022-01700-x · DOI · Paper page
  27. Duarte, 2022, Adapting serosurveys for the SARS-CoV-2 vaccine era, Open Forum Infect Dis, 9, 10.1093/ofid/ofab632 · DOI

Cited by

See all 173

Metadata

Authors
Lewis, H. C., Ware, H., Whelan, M., Subissi, L., Li, Z., Ma, X., Nardone, A., Valenciano, M., Cheng, B., Noel, K., Cao, C., Yanes-Lane, M., Herring, B. L., Talisuna, A., Ngoy, N., Balde, T., Clifton, D., Van Kerkhove, M. D., Buckeridge, D., Bobrovitz, N., Okeibunor, J., Arora, R. K., & Bergeri, I.
Venue
BMJ Global Health
Publisher
BMJ
Published
2022-08
Volume
7
Issue
8
Pages
e008793
ISSN
2059-7908 (ISSN-L)
OpenAlex
W4292774342
Cited by
173
References
10
FWCI
7.35
Type
journal article
Language
en
Open access
gold
Funders
  • World Health Organization (WHO COVID-19 Solidarity Response Fund)
  • Canadian Medical Association (Joule Innovation Fund)
  • Bundesministerium für Gesundheit, Germany (COVID-19 Research and Development Fund)
  • Robert Koch Institute Germany
  • Public Health Agency of Canada (Canada’s COVID-19 Immunity Task Force)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: SARS-CoV-2 infection in Africa: a systematic review and meta-analysis of standardised seroprevalence studies, from January 2020 to December 2021. https://app.cochat.ai/papers/10.1136/bmjgh-2022-008793
The paper
Lewis, H. C., Ware, H., Whelan, M., Subissi, L., Li, Z., Ma, X., Nardone, A., Valenciano, M., Cheng, B., Noel, K., Cao, C., Yanes-Lane, M., Herring, B. L., Talisuna, A., Ngoy, N., Balde, T., Clifton, D., Van Kerkhove, M. D., Buckeridge, D., . . . Bergeri, I. (2022). SARS-CoV-2 infection in Africa: a systematic review and meta-analysis of standardised seroprevalence studies, from January 2020 to December 2021. BMJ Global Health. https://doi.org/10.1136/bmjgh-2022-008793

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.